Incyte INCY announced new 24-week interim data from the STOP-HS program on pipeline candidate, povorcitinib (INCB54707), in ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

Incyte (INCY) announced new 24-week interim data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 ...

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa ...

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary ...